Clinical trials in Saronno – page 65

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Saronno at a glance

2 862

clinical trials

Research sites1

Quick filters

2 862 trials in Saronno

Open in trial search

Acute lymphocytic leukaemia

Recruiting

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Crisantaspase
Sponsor:Pfizer Inc.

Contact Research Centre

Gastrooesophageal cancer

Recruiting

Study on MK-2870, Pembrolizumab, and Chemotherapy for Patients with Advanced Gastroesophageal Cancer

Registered drugNo placebo

Study on MK-2870, Pembrolizumab, and Chemotherapy for Patients with Advanced Gastroesophageal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn's Disease

Investigational

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn's Disease

Investigational

Italy

Participants:0–17 years
Substances:Guselkumab
Sponsor:Janssen Cilag International

Contact Research Centre

Endometrial cancer+5

Recruiting

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

Registered drugNo placebo

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:AstraZeneca AB

Contact Research Centre

Atrial fibrillation+3

Recruiting

Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

Registered drugNo placebo

Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Insel Gruppe AG

Contact Research Centre

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Topotecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Cystic fibrosis

Recruiting

Study on the Safety and Effects of SPL84 for Patients with Cystic Fibrosis

Investigational

Study on the Safety and Effects of SPL84 for Patients with Cystic Fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Splisense Ltd.

Contact Research Centre

IgA nephropathy

Recruiting

Study on Atrasentan for Patients with IgA Nephropathy at Risk of Kidney Function Loss

Investigational

Study on Atrasentan for Patients with IgA Nephropathy at Risk of Kidney Function Loss

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Zigakibart
Sponsor:Novartis Pharma AG

Contact Research Centre

C3 glomerulopathy

Recruiting

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Iptacopan
Sponsor:Novartis Pharma AG

Contact Research Centre

BRAF V600E mutation positive+1

Recruiting

Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations

Registered drugNo placebo

Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cobicistat
Sponsor:Fore Biotherapeutics Inc.

Contact Research Centre

Von Willebrand's disease

Recruiting

Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa

Registered drugNo placebo

Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Octocog Alfa
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Glioblastoma multiforme

Recruiting

Long-term safety study of Temferon (modified stem cells with interferon-α2) in patients previously treated for glioblastoma multiforme

InvestigationalNo placebo

Long-term safety study of Temferon (modified stem cells with interferon-α2) in patients previously treated for glioblastoma multiforme

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Sponsor:Genenta Science S.p.A.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

MET deregulation therapy assessment
Second-line combination treatments
EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

Endocrine-responsive breast cancer treatment
Ovarian cancer maintenance therapy
BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

Metastatic renal cancer therapy
Atrial fibrillation management
Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Back to Italy All countries